Guo-hua Key Yu

Dr. Guo-hua Key Yu

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2021 in Frontiers in Nutrition
Verified
Journal Article
Open access
ZLZhiqiang Luo
Zhiqiang Luo
YLYang Liu
Yang Liu
XHXing Han
Xing Han
WYWenning Yang
Wenning Yang
GWGuopeng Wang
Guopeng Wang
YSYuanyuan Shi
Yuanyuan Shi
Screening functional food ingredients (FFI) from medicinal and edible plants (MEP) has still remained a great challenge due to the complexity of MEP and its obscure function mechanisms. Herein, an integrated strategy based on sequential metabolites identification approach, network pharmacology, molecular docking, and surface plasmon resonance (SPR) analysis was proposed for quickly identifying the active constituents in MEP. First, the sequential biotransformation process of MEP, including intestinal absorption and metabolism, and hepatic metabolism, was investigated by oral gavage, and intestinal perfusion with venous sampling method. Then the blood samples were analyzed by UPLC-Q Exactive Orbitrap HRMS. Second, the network pharmacology approach was used to explore the potential targets and possible mechanisms of the in vivo metabolites of MEP. Third, molecular docking and SPR approaches were used to verify the specific interactions between protein targets and representative ingredients. The proposed integrated strategy was successfully used to explore the heptoprotective components and the underlying molecular mechanism of Paeoniae Radix Alba (PRA). A total of 44 compounds were identified in blood samples, including 17 porotypes and 27 metabolites. The associated metabolic pathways were oxidation, methylation, sulfation, and glucuronidation. After further screening, 31 bioactive candidates and 377 related targets were obtained. In addition, the bioactive components contained in PRA may have therapeutic potentials for non-alcoholic fatty liver disease (NAFLD). The above results demonstrated the proposed strategy may provide a feasible tool for screening FFI and elaborating the complex function mechanisms of MEP.

1 May 2021 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
YHYing Hao
Ying Hao
YWYang Wu
Yang Wu
SWShanglong Wang
Shanglong Wang
CWChunguo Wang
Chunguo Wang
SQSihao Qu
Sihao Qu
YSYuanyuan Shi
Yuanyuan Shi

5 March 2023 in Molecular Biomedicine
Verified
Journal Article
Open access
PDF file
ZLZhiqiang Luo
Zhiqiang Luo
JSJiaru Shi
Jiaru Shi
QJQiyao Jiang
Qiyao Jiang
GYGuo-hua Key Yu
Guo-hua Key Yu
XLXiaorui Li
Xiaorui Li
YSYuanyuan Shi
Yuanyuan Shi
Chimeric antigen receptor T (CAR-T) cell targeting CD19 antigen has achieved exhilarative clinical efficacy in B-cell malignancies. However, challenges still remain for the currently approved anti-CD19 CAR-T therapies, including high recurrence rates, side effects and resistance. Herein, we aim to explore combinatorial therapy by use of anti-CD19 CAR-T immunotherapy and gallic acid (GA, an immunomodulatory natural product) for improving treatment efficacy. We assessed the combinatorial effect of anti-CD19 CAR-T immunotherapy with GA in cell models and a tumor-bearing mice model. Then, the underlying mechanism of GA on CAR-T cells were investigated by integrating network pharmacology, RNA-seq analysis and experimental validation. Furthermore, the potential direct targets of GA on CAR-T cells were explored by integrating molecular docking analysis with surface plasmon resonance (SPR) assay. The results showed that GA significantly enhanced the anti-tumor effects, cytokine production as well as the expansion of anti-CD19 CAR-T cells, which may be mainly through the activation of IL4/JAK3-STAT3 signaling pathway. Furthermore, GA may directly target and activate STAT3, which may, at least in part, contribute to STAT3 activation. Overall, the findings reported here suggested that the combination of anti-CD19 CAR-T immunotherapy with GA would be a promising approach to increase the anti-lymphoma efficacy.

1 January 2025 in The American Journal of Chinese Medicine
Verified
Journal Article
Closed access
JLJingming Li
Jingming Li
JZJingqi Zheng
Jingqi Zheng
YCYue Cui
Yue Cui
YLYang Liu
Yang Liu
HFHuixia Fan
Huixia Fan
ZLZhiqiang Luo
Zhiqiang Luo

13 March 2025 in Ecotoxicology and Environmental Safety
Verified
Journal Article
Open access
ZLZhiqiang Luo
Zhiqiang Luo
RJRuyi Jin
Ruyi Jin
FPFulu Pan
Fulu Pan
RGRuofan Guo
Ruofan Guo
MLMengyu Li
Mengyu Li
GYGuo-hua Key Yu
Guo-hua Key Yu
Ochratoxin A (OTA), the most toxic member of the ochratoxin family, is frequently detected in contaminated food and beverages, posing substantial health risks to both humans and animals, particularly due to its hepatotoxic effects. Although OTA is known to cause liver damage, the precise molecular mechanisms driving its toxicity remain poorly understood. In this study, we explored the hepatotoxic effects of OTA using LO2 cells and zebrafish models, combining miRNA and mRNA analyses to uncover the underlying mechanisms. Our results demonstrated that OTA significantly suppressed cell proliferation and viability, induced cell cycle arrest, triggered apoptosis and elevated reactive oxygen species (ROS) production in LO2 cells, with analogous apoptotic effects observed in zebrafish larvae. Additionally, miRNA-mRNA analysis revealed that differentially expressed genes (DEGs) and miRNAs (DEMs) were significantly enriched in pathways related to apoptosis, cell cycle regulation, and MAPK signaling. We constructed a potential regulatory network, identifying three key miRNAs (hsa-miR-3065-5p, hsa-miR-520g-3p, and hsa-miR-5698) and three associated hub mRNAs (CACNA1D, CDC6, and E2F1). Moreover, OTA treatment specifically induced p38 phosphorylation without significantly altering the phosphorylation levels of ERK or JNK. Collectively, this study established a comprehensive framework for understanding the hepatotoxic mechanisms of OTA at the miRNA and mRNA levels, providing critical insights into the pathogenesis of hepatotoxicity induced by ochratoxins and contributing to the prevention and management of related diseases.

7 February 2025 in Molecules
Verified
Journal Article
Open access
PDF file
XWXinyu Wang
Xinyu Wang
ZYZirong Yi
Zirong Yi
YZYiming Zhang
Yiming Zhang
JZJing Zhang
Jing Zhang
XLXueyan Li
Xueyan Li
GYGuo-hua Key Yu
Guo-hua Key Yu
Neuroinflammation is a significant driving force in the pathogenesis and progression of central nervous system (CNS) disorders. Polymethoxylated flavones (PMFs), the key lipid-soluble constituents in Citri Reticulatae Pericarpium (CRP), exhibit excellent blood–brain barrier permeability and anti-inflammatory properties, holding therapeutic potential for CNS disorders. However, the specific bioactive components and therapeutic effects of PMFs in treating CNS disorders are not well understood. This study employed a comprehensive sequential metabolism approach to elucidate the dynamic biotransformation of PMFs in vivo and identified seven brain-targeting components. Subsequently, network pharmacology and experimental validation were utilized to explore the potential mechanisms of PMFs. The results suggested that PMFs have potential therapeutic value for Alzheimer’s disease (AD)-like mice, with the inhibition of neuroinflammation likely being a key mechanism of their anti-AD effects. Notably, sinensetin, tangeretin, nobiletin, and 3,5,6,7,8,3′,4′-heptamethoxyflavone were identified as potent neuroinflammatory inhibitors. This research elucidated the chemical and therapeutic foundations of PMFs, indicating their potential as treatments or nutritional supplements for AD prevention and treatment. Moreover, the integrated triad approach of sequential metabolism, network pharmacology, and experimental validation may serve as a promising strategy for screening bioactive compounds in herbs or functional foods, as well as for elucidating their therapeutic mechanisms.